|
|
| Line 1: |
Line 1: |
| - | {{STRUCTURE_4brx| PDB=4brx | SCENE= }}
| + | ==Focal Adhesion Kinase catalytic domain in complex with a diarylamino- 1,3,5-triazine inhibitor== |
| - | ===Focal Adhesion Kinase catalytic domain in complex with a diarylamino- 1,3,5-triazine inhibitor===
| + | <StructureSection load='4brx' size='340' side='right' caption='[[4brx]], [[Resolution|resolution]] 2.05Å' scene=''> |
| - | {{ABSTRACT_PUBMED_23845217}}
| + | == Structural highlights == |
| | + | <table><tr><td colspan='2'>[[4brx]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4BRX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4BRX FirstGlance]. <br> |
| | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=KGW:2-(4-(2-METHOXY-4-MORPHOLINOPHENYLAMINO)-1,3,5-TRIAZIN-2-YLAMINO)-N-METHYLBENZAMIDE'>KGW</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
| | + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr> |
| | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4brx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4brx OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4brx RCSB], [http://www.ebi.ac.uk/pdbsum/4brx PDBsum]</span></td></tr> |
| | + | </table> |
| | + | <div style="background-color:#fffaf0;"> |
| | + | == Publication Abstract from PubMed == |
| | + | We report herein the synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK (focal adhesion kinase) inhibitors and the evaluation of their anti-angiogenic activity on HUVEC cells. Generally, the effects of these compounds on endothelial cells could be correlated with their kinase inhibitory activity. The most efficient compounds displayed inhibition of viability against HUVEC cells in the micromolar range, as observed with TAE-226, which was designed by Novartis Pharma AG. X-ray crystallographic analysis of the co-crystal structure for compound 34 revealed that the mode of interaction with the FAK kinase domain is highly similar to that observed in the complex of TAE-226. |
| | | | |
| - | ==Function==
| + | Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.,Dao P, Jarray R, Le Coq J, Lietha D, Loukaci A, Lepelletier Y, Hadj-Slimane R, Garbay C, Raynaud F, Chen H Bioorg Med Chem Lett. 2013 Jun 24. pii: S0960-894X(13)00759-2. doi:, 10.1016/j.bmcl.2013.06.038. PMID:23845217<ref>PMID:23845217</ref> |
| - | [[http://www.uniprot.org/uniprot/FAK1_CHICK FAK1_CHICK]] Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development, embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. Regulates axon growth and neuronal cell migration, axon branching and synapse formation; required for normal development of the nervous system. Plays a role in osteogenesis and differentiation of osteoblasts. Functions in integrin signal transduction, but also in signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), ephrin receptors, netrin receptors and LDL receptors. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascade. Promotes activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling cascade. Promotes localized and transient activation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), and thereby modulates the activity of Rho family GTPases. Signaling via CAS family members mediates activation of RAC1. Regulates P53/TP53 activity and stability. Phosphorylates SRC; this increases SRC kinase activity. Isoform 2 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling.<ref>PMID:15494733</ref> <ref>PMID:15494734</ref> <ref>PMID:15494732</ref> <ref>PMID:20705914</ref> <ref>PMID:21852560</ref> <ref>PMID:21937583</ref>
| + | |
| | | | |
| - | ==About this Structure==
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
| - | [[4brx]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4BRX OCA].
| + | </div> |
| | | | |
| - | ==Reference== | + | ==See Also== |
| - | <ref group="xtra">PMID:023845217</ref><references group="xtra"/><references/>
| + | *[[Focal adhesion kinase|Focal adhesion kinase]] |
| | + | == References == |
| | + | <references/> |
| | + | __TOC__ |
| | + | </StructureSection> |
| | [[Category: Gallus gallus]] | | [[Category: Gallus gallus]] |
| | [[Category: Non-specific protein-tyrosine kinase]] | | [[Category: Non-specific protein-tyrosine kinase]] |
| - | [[Category: Coq, J Le.]] | + | [[Category: Coq, J Le]] |
| - | [[Category: Lietha, D.]] | + | [[Category: Lietha, D]] |
| | [[Category: Atp-binding]] | | [[Category: Atp-binding]] |
| | [[Category: Integrin signaling]] | | [[Category: Integrin signaling]] |
| | [[Category: Kinase inhibitor]] | | [[Category: Kinase inhibitor]] |
| | [[Category: Transferase]] | | [[Category: Transferase]] |
| Structural highlights
Publication Abstract from PubMed
We report herein the synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK (focal adhesion kinase) inhibitors and the evaluation of their anti-angiogenic activity on HUVEC cells. Generally, the effects of these compounds on endothelial cells could be correlated with their kinase inhibitory activity. The most efficient compounds displayed inhibition of viability against HUVEC cells in the micromolar range, as observed with TAE-226, which was designed by Novartis Pharma AG. X-ray crystallographic analysis of the co-crystal structure for compound 34 revealed that the mode of interaction with the FAK kinase domain is highly similar to that observed in the complex of TAE-226.
Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.,Dao P, Jarray R, Le Coq J, Lietha D, Loukaci A, Lepelletier Y, Hadj-Slimane R, Garbay C, Raynaud F, Chen H Bioorg Med Chem Lett. 2013 Jun 24. pii: S0960-894X(13)00759-2. doi:, 10.1016/j.bmcl.2013.06.038. PMID:23845217[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Dao P, Jarray R, Le Coq J, Lietha D, Loukaci A, Lepelletier Y, Hadj-Slimane R, Garbay C, Raynaud F, Chen H. Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity. Bioorg Med Chem Lett. 2013 Jun 24. pii: S0960-894X(13)00759-2. doi:, 10.1016/j.bmcl.2013.06.038. PMID:23845217 doi:10.1016/j.bmcl.2013.06.038
|
